Lumenis Announces Nasdaq Hearing Date

Lumenis Announces Nasdaq Hearing Date 


YOKNEAM, Israel, Dec. 5  /PRNewswire-FirstCall/ -- Lumenis Ltd.  announced today
that the hearing with a Nasdaq Listing Qualifications Panel has been set for
December 18, 2003.  As previously announced, Lumenis had intended to appeal at
the hearing a letter received from the Staff of Nasdaq stating its securities
are subject to delisting since the interim financials in the Company's Form 10-Q
for the quarter ended September 30, 2003 had not been reviewed by the Company's
independent auditors in accordance with SEC Rules due to an ongoing independent
investigation being conducted by its Audit Committee.

Pending the hearing and the Panel's determination, the Company's shares will
continue to be listed on The Nasdaq National Market and quoted under the trading
symbol LUMEE.

  The Audit Committee is working expeditiously to complete its investigation.

  About Lumenis


Lumenis develops, manufactures, and markets state-of-the-art proprietary laser
and intense pulsed light devices. Its systems are used in a variety of
aesthetic, ophthalmic, surgical and dental applications, including skin
treatments, hair removal, non-invasive treatment of vascular lesions and
pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign
prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary
cataracts, age-related macular degeneration, vision correction, neurosurgery,
dentistry and veterinary. For more information about the Company and its
products log on to http://www.lumenis.com/ .

The statements in this press release that are not historical facts are
forward-looking statements which are subject to risks and uncertainties. The
Company's actual results could differ materially from those anticipated in the
forward looking statements based on a variety of factors, including, among
others: uncertainties with respect to market acceptance of the Company's
products, obtaining regulatory approvals for new products or for the sale of
existing products in new markets and enforcement of intellectual property
rights; risks associated with competition and competitive pricing pressures,
economic conditions generally, the Company's international operations and the
Company's ability to integrate its operations with those of acquired businesses;
the outcome of the Securities and Exchange Commission investigation and several
securities class action lawsuits to which the Company is subject; uncertainties
relating to the Company's continuing liquidity; and other risks detailed from
time to time in the reports filed by Lumenis with the SEC, including its annual
report on Form 10-K and quarterly reports on Form 10-Q.

   Contact:  Kevin Morano
             CFO
             212-515-4187/


DATASOURCE: Lumenis Ltd.



CONTACT:  Kevin Morano, CFO of Lumenis Ltd., [phone]



Web Site:  http://www.lumenis.com/ 

Copyright